Claims data analysis of dosing and cost of TNF antagonists

American Journal of Pharmacy Benefits

Volumn 2, Issue 6, 2010, Pages 351-359

  Gu, Ning Yan ^a   Huang, Xing Yue ^b   Fox, Kathleen M ^c   Patel, Vaishali D ^d   Baumgartner, Scott W ^d   Chiou, Chiou Fang ^d  

^a PHARMERIT INTERNATIONAL   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Strategic Healthcare Solutions LLC   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CLINICAL PRACTICE; DATA ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT SELECTION; PHARMACY; RHEUMATOID ARTHRITIS;

EID: 78751479768     PISSN: 19454481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Enbrel (etanercept) prescribing information. Thousand Oaks, CA: Immunex Corporation; 2007. http://www.enbrel.com. Accessed June 5, 2007.
2. Humira (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories; 2007. http://www.humira.com. Accessed June 5, 2007.
3. Remicade (infliximab) prescribing information. Malvern, PA: Centocor, Inc; 2006. http://www.remicade.com. Accessed September 5, 2006.
4. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343(22):1594-1602.
5. Klareskog L, van der Heijde D, de Jager JP, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomized controlled trial. Lancet. 2004;363(9410):675-681.
6. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human antitumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [published correction appears in Arthritis Rheum. 2003;48(3):855]. Arthritis Rheum. 2003; 48(1):35-45.
7. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol. 2004;3(8):1538-1545.
8. Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(6):1451-1459.
9. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24(11):1720-1740.
10. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical responses to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921-926.
11. Ollendorf DA, Massarotti E, Birbara C, Burgess SM. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm. 2005;11(5):383-393.
12. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez-Arboleya L, Navarro-Compán V, Toyos J. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford). 2007;46(3):529-532.
13. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373-383.
14. Berger A, Edelsberg J, Li, TT, Maclean JR, Oster G. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother. 2005;39(12): 2021-2025.
15. Weycker D, Yu EB, Wooley JM, Oster G. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged>65 years with rheumatoid arthritis. Clin Ther. 2005;27(5):646-656.
16. Harley CR, Frytak R, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9(6 suppl):S136-S143.
17. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Cohen MD. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm. 2004;10(6):538-542.
18. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12(7): 555-569.